Brief: Transcode Therapeutics Announces First Subject Dosed With Radiolabeled Ttx-Mc138 In First-In-Human Clinical Trial
23/08/2023 13:06
Aug 23 (Reuters) -
* TRANSCODE THERAPEUTICS ANNOUNCES FIRST SUBJECT DOSED WITH
RADIOLABELED TTX-MC138 IN FIRST-IN-HUMAN CLINICAL TRIAL
* TRANSCODE THERAPEUTICS INC - PHASE 1 TRIAL PLANNED TO
COMMENCE
IN 2024
Source text for Eikon: ID:nGNX4J4C8N
Further company coverage: RNAZ.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors